Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Controlled Trial of Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab in Third-line or Later-line Treatment of Advanced Gastric Adenocarcinoma

NCT05095636 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05095636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05095636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Controlled Trial of Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab in Third-line or Later-line Treatment of Advanced Gastric Adenocarcinoma
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
March 17, 2021
Completion date
September 30, 2023
Enrollment
102 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, metastasis